Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- Introduction
- 1 Bipolar disorder in historical perspective
- 2 The bipolar spectrum
- 3 Defining and measuring Bipolar II Disorder
- 4 Bipolar II Disorder in context: epidemiology, disability and economic burden
- 5 Is Bipolar II Disorder increasing in prevalence?
- 6 The neurobiology of Bipolar II Disorder
- 7 The role of antidepressants in managing Bipolar II Disorder
- 8 The use of SSRIs as mood stabilisers for Bipolar II Disorder
- 9 Mood stabilisers in the treatment of Bipolar II Disorder
- 10 The use of atypical antipsychotic drugs in Bipolar II Disorder
- 11 The role of fish oil in managing Bipolar II Disorder
- 12 The role of psychological interventions in managing Bipolar II Disorder
- 13 The role of wellbeing plans in managing Bipolar II Disorder
- 14 Survival strategies for managing and prospering with Bipolar II Disorder
- 15 A clinical model for managing Bipolar II Disorder
- 16 Management commentary
- 17 Management commentary
- 18 Management commentary
- 19 Management commentary
- 20 Management commentary
- 21 Management commentary
- 22 Management commentary
- 23 Management commentary
- 24 Management commentary
- 25 Management commentary
- 26 Management commentary: What would Hippocrates do?
- 27 Management commentary
- 28 Rounding up and tying down
- Appendix 1 Black Dog Institute Self-test for Bipolar Disorder: The Mood Swings Questionnaire
- Index
- References
10 - The use of atypical antipsychotic drugs in Bipolar II Disorder
Published online by Cambridge University Press: 13 August 2009
Edited by
Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- Introduction
- 1 Bipolar disorder in historical perspective
- 2 The bipolar spectrum
- 3 Defining and measuring Bipolar II Disorder
- 4 Bipolar II Disorder in context: epidemiology, disability and economic burden
- 5 Is Bipolar II Disorder increasing in prevalence?
- 6 The neurobiology of Bipolar II Disorder
- 7 The role of antidepressants in managing Bipolar II Disorder
- 8 The use of SSRIs as mood stabilisers for Bipolar II Disorder
- 9 Mood stabilisers in the treatment of Bipolar II Disorder
- 10 The use of atypical antipsychotic drugs in Bipolar II Disorder
- 11 The role of fish oil in managing Bipolar II Disorder
- 12 The role of psychological interventions in managing Bipolar II Disorder
- 13 The role of wellbeing plans in managing Bipolar II Disorder
- 14 Survival strategies for managing and prospering with Bipolar II Disorder
- 15 A clinical model for managing Bipolar II Disorder
- 16 Management commentary
- 17 Management commentary
- 18 Management commentary
- 19 Management commentary
- 20 Management commentary
- 21 Management commentary
- 22 Management commentary
- 23 Management commentary
- 24 Management commentary
- 25 Management commentary
- 26 Management commentary: What would Hippocrates do?
- 27 Management commentary
- 28 Rounding up and tying down
- Appendix 1 Black Dog Institute Self-test for Bipolar Disorder: The Mood Swings Questionnaire
- Index
- References
Summary
Introduction
The bipolar disorders are common, severe long-term conditions, with the World Health Organization reporting in 2001 that bipolar disorder was the fifth cause of ‘life years lived with a disability’ among young adults (WHO, 2001). Atypical antipsychotics are established as the main treatment for schizophrenia, but recently a growing number of trials have indicated that they may provide a therapeutic option for bipolar disorder, as both alternative and adjunctive treatments to traditional mood stabilisers (Vieta and Goikolea, 2005; Berk and Dodd, 2005). While they have been most commonly assessed as treatments for mania, there is increasing evidence of their efficacy and safety in the treatment of bipolar depression and as maintenance treatments of bipolar disorder.
The availability of atypical antipsychotics has brought important changes in the management of the bipolar disorders. Firstly, methodologically more rigorous trials have been developed in order to research their efficacy and safety as a treatment for the different bipolar phases. Secondly, the use of atypical antipsychotics in patients with schizophrenia has given short-term and long-term results suggesting that they provide a safer option than typical antipsychotics. Thirdly, it has been suggested that atypical antipsychotics, via neuronal plasticity determinant molecules, may relate to the therapeutic response process observed in drugs more commonly used as a treatment of affective disorders (Vieta, 2003). Fourthly, some atypical antipsychotics may have mood-stabilising properties (Yatham et al., 2005).
Special characteristics of Bipolar II Disorder
There are several special characteristics of Bipolar II (BP II) Disorder that have important clinical consequences.
- Type
- Chapter
- Information
- Bipolar II DisorderModelling, Measuring and Managing, pp. 133 - 140Publisher: Cambridge University PressPrint publication year: 2008
References
, , et al. (1995). Antidepressant-induced mania and cycle acceleration: a controversy revisited. American Journal of Psychiatry, 152, 1130–8.Google ScholarPubMed
and (2005). Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of Bipolar Type I and Type II major depression – lack of manic induction. Journal of Affective Disorders, 87, 121–30.CrossRefGoogle ScholarPubMed
and (2005). Efficacy of atypical antipsychotics in bipolar disorder. Drugs, 65, 257–69.CrossRefGoogle ScholarPubMed
(2005). Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. Journal of Clinical Psychiatry, 66 (Suppl. 3), S12–19.Google ScholarPubMed
, , et al. (2006). A seven-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of Bipolar I depression. Journal of Clinical Psychiatry, 67, 1025–33.CrossRefGoogle Scholar
and (2007). Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Progress in Neuropsychopharmacological and Biological Psychiatry, 31, 275–82.CrossRefGoogle ScholarPubMed
(1979). Rapid-cycling manic depressive illness. Psychiatric Clinics of North America, 2, 461–7.Google Scholar
, , and (2006). Bipolar II Disorder: current and future treatment options. Annals of Clinical Psychiatry, 18, 259–66.CrossRefGoogle ScholarPubMed
, , et al. (2006). Role of aripiprazole in treating mood disorders. Expert Review of Neurotherapeutics, 6, 1777–83.CrossRefGoogle ScholarPubMed
, and (2000). Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. Journal of Clinical Psychiatry, 61, 804–8.CrossRefGoogle ScholarPubMed
, , and (2003). Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders, 5, 421–33.CrossRefGoogle ScholarPubMed
, and (2004). Pharmacotherapy of Bipolar II Disorder: a critical review of current evidence. Bipolar Disorders, 6, 14–25.CrossRefGoogle ScholarPubMed
(2004). Bipolar depression: the real challenge. European Neuropsychopharmacology, 14, 83–8.CrossRefGoogle ScholarPubMed
, , and for the BOLDER Study Group (2006). Quetiapine in the treatment of anxiety in patients with Bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 67, 355–62.CrossRefGoogle ScholarPubMed
, , et al. (2002). The long-term natural history of the weekly symptomatic status of Bipolar I Disorder. Archives of General Psychiatry, 59, 530–7.CrossRefGoogle ScholarPubMed
, , , and (2003). Rapid- and non-rapid-cycling bipolar disorder: A meta-analysis of clinical studies. Journal of Clinical Psychiatry, 64, 1483–94.CrossRefGoogle ScholarPubMed
(1988). Rapid-cycling Bipolar II illness in three closely related individuals. American Journal of Psychiatry, 145, 114–15.Google ScholarPubMed
, , et al. (2004). The antidepressant effects of risperidone and olanzapine in bipolar disorder. Canadian Journal of Clinical Pharmacology, 11, e218–26. Epub., October 4.Google ScholarPubMed
, and (2006). Add-on quetiapine for bipolar depression: a 12-month open-label trial. Canadian Journal of Psychiatry, 51, 523–30.CrossRefGoogle ScholarPubMed
and (2005). Maintenance therapies in bipolar disorder: focus on randomised controlled trials. Australian and New Zealand Journal of Psychiatry, 39, 652–61.CrossRefGoogle Scholar
, , et al. (2000). Long-term effects of the treatment with risperidone versus conventional neuroleptics on the neuropsychological performance of euthymic bipolar patients. Actas Españolas de Psiquiatría, 28, 231–8.Google ScholarPubMed
, , et al. (2006). Quetiapine monotherapy for depressive episodes in Bipolar II Disorder: combined results from two placebo-controlled studies. Bipolar Disorders, 8 (Suppl. 1), S34–5.Google Scholar
, , et al. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of Bipolar I depression. Archives of General Psychiatry, 60, 1079–88.CrossRefGoogle ScholarPubMed
, , et al. (2006). Cognitive impairment in Bipolar II Disorder. British Journal of Psychiatry, 189, 254–9.CrossRefGoogle ScholarPubMed
(2003). Atypical antipsychotics in the treatment of mood disorders. Current Opinion in Psychiatry, 16, 23–7.CrossRefGoogle Scholar
(2007). Managing Bipolar Disorder in Clinical Practice. London: Current Medicine Group.Google Scholar
and (2005). Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disorders, 7 (Suppl. 2), S1–S13.CrossRefGoogle ScholarPubMed
, , , and (1997). Differential features between Bipolar I and Bipolar II disorder. Comprehensive Psychiatry, 38, 98–101.CrossRefGoogle ScholarPubMed
, , et al. (2001). Role of risperidone in Bipolar II: an open six-month study. Journal of Affective Disorders, 67, 213–19.CrossRefGoogle Scholar
World Health Organization (2001). World Health Report: Mental Health: New Understanding, New Hope. Geneva: World Health Organization.
., , et al. (2005). Atypical antipsychotics in bipolar depression: potential mechanisms of action. Journal of Clinical Psychiatry, 66, 40–8.Google ScholarPubMed
, , et al. (2006). Guidelines Group, CANMAT. Canadian Network for Mood and Anxiety Treatments guidelines for the management of patients with bipolar disorder: Update 2007. Bipolar Disorders, 8, 721–39.CrossRefGoogle ScholarPubMed
, , et al. (2005). CANMAT. Canadian Network for Mood and Anxiety Treatments guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders, 7 (Suppl. 3), S5–69.CrossRefGoogle ScholarPubMed